Using the conditional BRAF oncogene-driven murine melanoma model, this work demonstrates that co-treatment of the MEK inhibitor trametinib along with the autophagy inhibitor chloroquine induced an enhanced therapeutic effect. This evidence concerns the gene MAP2K7 and melanoma.